HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Cancer immunotherapy represents a groundbreaking approach in the field of cancer treatment. Unlike traditional methods such as surgery, chemotherapy, or radiation therapy, immunotherapy harnesses the body's own immune system to combat cancer cells. At its core, the immune system is a complex network of cells, tissues, and organs designed to protect the body from harmful invaders. Cancer cells, however, can evade detection and suppression by the immune system. Immunotherapy works by stimulating the immune system or enhancing its natural abilities to recognize and destroy cancer cells. One key aspect of cancer immunotherapy involves checkpoint inhibitors, which are drugs that block certain proteins on cancer cells or immune cells, allowing the immune system to recognize and attack the cancer. Another approach is adoptive cell transfer, where immune cells, such as T cells, are extracted, modified, and then reintroduced into the patient to enhance their cancer-fighting capabilities. CAR-T cell therapy is a notable example, where T cells are engineered to express chimeric antigen receptors (CARs) to specifically target cancer cells. This personalized approach has shown promising results in treating certain types of blood cancers. Furthermore, cancer vaccines aim to stimulate the immune system to recognize and attack cancer cells. These vaccines may contain antigens specific to cancer cells or utilize the patient's own cells to trigger an immune response against the cancer. While cancer immunotherapy has demonstrated remarkable success in some cases, challenges remain. Response rates can vary among different types of cancer, and not all patients benefit equally. Additionally, managing potential side effects and understanding the long-term effects of immunotherapy are areas of ongoing research.
